Project Grant R15CA290578
Award Date
7/9/25
Completion Date
5/31/28
Dollars Obligated
$451K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug that selectively delivers a potent cytotoxin to tumor cells expressing hyperactive membrane-anchored serine proteases. The goal is to create an effective therapeutic strategy to target metastatic solid tumors, including ovarian, lung, and colon cancers, which often respond poorly to current...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $186,250 to the University of Virginia to develop and characterize fluorescent probes that can measure the local membrane environments surrounding membrane proteins in living cells. The goal is to create an experimental toolbox to probe how membrane proteins assemble and regulate their local lipid environments, known as "paralipidomes." The award will fund a two-year research...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $432,889 to The Johns Hopkins University to conduct research aimed at advancing cancer screening, diagnostic technologies, and early detection methodologies. The project, titled "Molecular Imaging and Metabolotheranostics of PDAC-Induced Cachexia", will focus on reversing cachexia (severe muscle wasting) induced by pancreatic ductal adenocarcinoma...
The National Cancer Institute (NCI) awarded a $671,072 Project Grant under CFDA 93.394 (Cancer Detection and Diagnosis Research) to the University of Washington (UW) to develop a novel ultra-miniaturized device termed "Picoliter Thin-Layer Chromatography (PTLC)" for high-throughput and sensitive analysis of lipid signaling in single cells from patient samples. This 5-year award, effective April 1, 2025, will leverage micro- and nano-fabrication techniques to create an easy-to-use,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 Cancer Detection and Diagnosis Research) provides $597,766 to The Trustees of the University of Pennsylvania to develop novel methods for dual-tracer PET imaging to better characterize cancer. The key objectives are to: 1) Develop protocols to image fluoroglutamine and FDG in breast cancer patients using a long-axial field-of-view PET scanner to enable quantitative analysis of tumor metabolism, and 2) Develop...
The National Cancer Institute (NCI) awarded a Project Grant, under CFDA 93.394 Cancer Detection and Diagnosis Research, to Case Western Reserve University (CWRU) for $654,681 starting on December 1, 2024. The goal of this 5-year project is to develop innovative anticancer nanovaccines utilizing multifunctional ionizable lipid nanoparticles for the curative treatment of pancreatic ductal adenocarcinoma (PDAC). The research aims to design and evaluate these nanovaccines, assess their therapeutic...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $402,401.00 to Emory University to develop a PET CCR2 imaging agent to profile the tumor microenvironment of pancreatic ductal adenocarcinoma (PDAC). The project aims to advance diagnostic and profiling capabilities for this highly aggressive cancer, which is the 4th leading cause of cancer-related death. The award has a period of performance from July 4, 2024 to...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $452,540 to the Sloan-Kettering Institute for Cancer Research to develop a novel T-cell imaging paradigm that will enable real-time monitoring of endogenous T-cell trafficking, tumor targeting, and persistence in patients with multiple myeloma undergoing bispecific T-cell engager antibody (BiTEA) treatments. The goal is to better understand mechanisms of therapy...
The National Cancer Institute (NCI) awarded a $632,300 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Carnegie Mellon University. The grant will fund the development of an integrated ultrahigh-throughput 3D volumetric super-resolution imaging system. This system will combine a multiscale fluorescence mesoscope with magnify expansion microscopy to enable rapid, large-area 3D imaging with exceptional subcellular detail. The goal is to study interactions between cancer and...
The University of Colorado-Denver was awarded a $375,134 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to investigate a novel approach for reducing off-target accumulation of chemotherapeutic nanomedicines. The key objectives are to characterize the innate immune response that can tighten epithelial barriers and limit nanoparticle deposition in healthy tissues, and to leverage this response to enhance delivery of chemotherapeutic agents to tumors...